Clinical trials internet resource
November 2004
References
[1] Medical Research Council. MRC Guidelines for Good Clinical Practice in Clinical Trials. London: MRC, 1998.
[2] Doyal L and Tobias JS. Informed consent in medical research. London: BMJ Books, 2001.
[3] Jenkins V A, Fallowfield L, Souhami A, and Sawtell M. How do doctors explain randomised clinical trials to their patients? European Journal of Cancer 1999;35:1187-93.
[4] Pharmaceutical Industry Competitiveness Task Force. Final Report, March, 2001.
[5] Pharmaceutical Industry Competitiveness Task Force. Competitiveness and Performance indicators 2003,
Download as a pdf here - www.advisorybodies.doh.gov.uk/pictf/pictf_indicators.pdf, accessed 29/10/04.
[6] Slevin M, Mossman J, Bowling A, Leonard R, Steward W, Harper P, McIllmurray M, and Thatcher N. Volunteers or victims: patients’ views of randomised cancer clinical trials. British Journal of Cancer 1995;71:1270-4.
[7,8] Fallowfield L, Ratcliffe D and Souhami R. Clinicians’ attitudes to clinical trials of cancer therapy. European Journal of Cancer 1997;33:2221-9, Hancock B, Aitken M, Radstone C, and Vaughan Hudson G. Why don’t cancer patients get entered into clinical trials? Experience of the Sheffield Lymphoma Group’s collaboration in British National Lymphoma Investigation studies. BMJ 1997;314:36.
[9] Prescott RJ, Counsell CE, Gillespie WJ, Grant AM, Russell IT and Ross S. Improving the quality, number and progress of randomised controlled trials. In L Duley and B Farrell (Eds) Clinical Trials. London: BMJ Books, 2002.
[10,11] Shea S, Bigger JT Jr, Campion J et al. Enrolment in clinical trials: institutional factors affecting enrolment in the cardiac arrhythmia suppression trial. Controlled Clinical Trials 1992;13:466-86, Penn ZJ, Steer PJ. Reasons for declining participation in prospective randomised trial to determine the optimum delievery of the preterm breech. Controlled Clinical Trials 1990;11:226-31.
[12,13] Smyth J F, Mossman J, Hall R, Hepburn S, Pinkerton R, Richards M, Thatcher N, and Box J. Conducting clinical research in the new NHS: the model of cancer. BMJ 1994;309:457-61, Tobias JS, Baum M and Thornton H. Clinical Trials in Cancer: What makes for a successful study? Annals of Oncology 2000;11:1371-3.
[14] Angell M. Patients’ preferences in randomised clinical trials. New England Journal of Medicine 1984;310:1385-7
[15] Freedman B. Equipoise and the ethics of clinical research. New England Journal of Medicine 1987;317:141-5
[16] Ward J. GPs’ experience of research. Family Practice 1994;11:418-23.
[17] Chalmers I. It’s official: evaluative research must become part of routine care in the NHS. Journal of the Royal Society of Medicine 2000;93:555-4.
[18] Thornton H. Randomized Clinical Trials: The Patient’s Point of View. In Silverstein M J Ductal Carcinoma in Situ of the Breast 1997.
[19] Wager E, Tooley PJH, Emanuel MB and Wood SF. How to get patients’ consent to enter clinical trials. BMJ 1995;311:734-7.
[20] Andrew F, Riordan I, Alistair P, Thomson J. How to get patients’ consent to enter clinical trials [letter]. BMJ 1996;312:185-6.
[21, 22,23] Stiller CA. Centralised treatment, entry to trials and survival. British Journal of Cancer 1994;70:352-62, Lantos J. The inclusion benefit in clinical trials. Journal of Pediatrics 1999; 134:130-1, Braunholtz DA, Edwards SJL and Lilford RJ. Are randomised clinical trials good for us (in the short term)? Evidence for a ‘trial effect’. Journal of Clinical Epidemiology 2001;54:217-24.
[24,25] Bugeja G, Kumar A, Banerjee AK. Exclusion of elderly people from clinical research: a descriptive study of published reports. BMJ 1997;315:1059, Bayer A, Tadd W. Unjustified exclusion of elderly people from studies submitted to research ethics committee for approval: descriptive study. BMJ 2000;321:992-3.
[26] Cockburn J, Redman S, and Kricker A. Should women take part in clinical trials in breast cancer? Issues and some solutions. Journal of Clinical Oncology 1998;16:354-62.
[27] Horn J, de Haan RJ, Vermeulen M, Luiten PG and Limburg M. Nimodipine in animal model experiments of focal cerbral ischemis: A systematic review. Stroke 2001;32:2433-8
[28] McNamee D. Public perceptions of RCTs. Lancet 1998;351:772.
[29] Welton A J, Vickers M R, Cooper J A, Meade T W and Marteau T M. Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasi-randomised, interview based study. BMJ 1999;318:1114-7
[30] Roland M. What are pragmatic trials? (Methods of randomised controlled trials, part 2). BMJ 1998;316:285.
[31] Tannock I F. The recruitment of patients into clinical trials. British Journal of Cancer 1995;71:1134-5.
[32] Hanley B, Truesdale A, King A, Elbourne D, and Chalmers I. Involving consumers in designing, conducting, and interpreting randomised clinical trials: questionnaire survey. BMJ 2001;322:519-23.
[33] NHS Executive. Research: What’s in it for consumers? London: Department of Health, 1998.
[34] General Medical Council. Research: The role and responsibilities of doctors. London: GMC, 2002.
[35] Parmar, M (2002) personal correspondence. Dr. Max Parmar was one of the reviewers for the first BMA Clinical Trials Internet Resource in 2002.
[36] Smith, R. Maintaining the integrity of the scientific record. BMJ 2001;323:588.
[37] Association of the British Pharmaceutical Industry. Scientific independence of clinical trial researchers: ABPI Statement, September 12 2001.
[38] Department of Health. Research Governance Framework for Health and Social Care, London, Department of Health, 2001
[39] International Conference on Harmonisation Harmonised Tripartite Guideline. Guidelines for Good Clinical Practice. ICH, 1996.